Drug intelligence / Profile preview

99mTc-3PRGD2

Development stage: Phase 3
Lead developer: Beijing Pharbers Genesis Pharmaceutical Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

99mTc-3PRGD2 is a radiopharmaceutical diagnostic agent composed of a pegylated arginine-glycine-aspartic acid (RGD) dimer labeled with technetium Tc 99m. It targets the integrin αvβ3 receptor, which is overexpressed in tumor angiogenesis and certain cancer cells. This agent is used primarily for single-photon emission computed tomography (SPECT/CT) imaging to detect tumors, evaluate tumor response to therapy, and image angiogenesis. It has been studied extensively in lung cancer diagnosis and evaluation of lymph node metastases. The tracer exhibits rapid blood clearance mainly via renal excretion and shows good imaging quality with low background uptake in lungs and mediastinum facilitating lesion detection.

Other names: Technetium Tc 99m-3PRGD2Technetium-99 niacinamide polyethylene glycol bicyclic RGD peptideTechnetium99 niacinamide polyethylene glycol bicyclic RGD peptideTechnetium 99 niacinamide polyethylene glycol bicyclic RGD peptide

Targets

αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on 99mTc-3PRGD2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-3PRGD2.

Explore the full profile